IAM Issue 93

November/December 2018

Doing intellectual property the Dolby Labs way

For over half a century Dolby Labs has worked hard to ensure that the company’s IP strategy is always aligned with its overall business goals. Its success in doing this teaches valuable lessons.

Features

Patents, platform technologies and new therapeutic modalities

The pace of change in the life sciences industry is startling and is putting traditional IP management strategies under extreme pressure. It may be time for IP leaders to start looking to the tech industry experience for lessons in how to respond.

IP risk management goes mainstream and some see big bucks ahead

Insurance products relating to patents and other rights are not new, but they have never really taken off. Now, though, the industry's heavy hitters are moving in and things could be about to change.

The 2018 brokered patent market

“The patent market has fully stabilised and prices are rational,” said no one ever. During 2018 total dollars transacted in brokered deals increased while prices of single-asset deals have dropped significantly.

A director’s guide to modernising IP governance frameworks

Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.

Doing intellectual property the Dolby Labs way

For over half a century Dolby Labs has worked hard to ensure that the company’s IP strategy is always aligned with its overall business goals. Its success in doing this teaches valuable lessons.

Licensing SEPs for the Internet of Things

Interconnectivity is the key to maximising IoT's potential - and that means finding effective ways to ensure access to the IP required to make it happen.

Why the EPO should decide which SEPs are essential

The heads of intellectual property at Swedish automaker Volvo Car Corporation and Swiss wireless communications supplier u-blox AG believe that the EPO must play a central role in deciding on mobile technology SEPs.

US pharma patents are under greater threat than ever before

Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.

Is McCurdy the man to rescue RPX?

Just months after a private equity takeover, RPX has appointed an industry veteran as its new CEO. But with a declining financial performance and questions remaining over the future of its discovery business, Dan McCurdy (left) will need all of his experience to turn around one of the patent market’s most iconic businesses.

Open source practices to support in-house innovation

How to ensure that the use of open source packages does not run contrary to corporate IP policies.

Columns

Why failure is IP’s most underrated asset

Negative know-how, an often-overlooked trade secret, can generate surprising value, especially where competition is most heated.

Re-conceptualising IP risk management

The scale and size of the risks associated with IP-facing companies is significant and rising. The ISO standard for risk management helps to re-conceptualises it.

Is the tide turning against pharmaceutical patentees in Australia?

A pair of recent decisions from the Federal Court of Australia suggest that it may be about to become more difficult for drug patent owners to prevail in requests for interlocutory injunctions.

Insights

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.

IP market news highlights

Some of the major stories carried on the IAM platform in October and November.

Data Centre

IP-related statistics from the recent past

A selection of key IP facts and figures, as reported by IAM and other sources.